Hi, everyone. Welcome to the Jefferies 2026 Healthcare Conference. Thank you for coming. We are pleased to have Stefan Weber, CEO of Newron Pharma. Thank you.
Thank you to Jefferies and to all of you for attending this update on Newron Pharmaceuticals. My absolute pleasure. This is 26 years of CNS research and development. We are headquartered in Milan, Italy, with a 100% subsidiary in Morristown, New Jersey. We are listed on the Swiss Exchange since 2006, one of the top three global IPOs at the time, with ambitions to have our shares listed on NASDAQ as the news flow supports. Given the long time of the company's existence, you would expect some proof of success, and yes, we do have a drug on the market for 10 years now in Europe, for eight years in the United States. It is XADAGO, brand name. It is an add-on treatment to levodopa in Parkinson's patients with motor fluctuations. Has collected more than $100 million of royalties so far and is going to do that for another few years.
But as I said, it is licensed globally, so there won't be a major leverage for investors. Takes us to the next compound, evenamide, which comes from the same class of compounds as XADAGO. This is going to be a transformative treatment for poorly responding and treatment-resistant schizophrenia patients, which, by the way, is the vast majority of all schizophrenic patients. The vast majority is not sufficiently or not at all benefiting from today's medications. We do have absolutely thrilling first-ever one-year results from phase II study as an add-on to treatment-resistant schizophrenia, and we already have the first highly statistically significant results from the phase III study in 11 countries in patients who are poorly responding to today's antipsychotics. You will see results from the global, and that makes us the most advanced program today in schizophrenia, one of the very few independent companies with a schizophrenia project.
You will see results from our global 1,000 patients total, two pivotal studies next year, Q1, Q2, Q3, and we come to that in a second. 12 weeks, 26 weeks results, and 12 weeks from the second pivotal study, Q1, Q2, Q3 next year. The team has done it before. Our chief medical has been with Novartis, Roche, and Organon. Our vice president commercial affairs has with J&J lifelong, fully independent board headed by Chris Martin, a successful serial entrepreneur. So, what is really so special about the evenamide opportunity? It is a combination of three things. It is a first-in-class glutamatergic modulator in a world in schizophrenia that is substantially dominated by dopaminergic mechanistic and lately cholinergic mechanistics. A large market, no need to discuss. Every drug on the market qualifies as a blockbuster. So this is the new mechanism, glutamatergic modulation, leaving completely unaffected the basal levels of glutamate.
That is why we are one of the very few. The other one that I'm aware of is Lilly's esketamine. It's one of the very few drugs that have shown to work safely with glutamatergic mechanism. It will qualify as the first add-on treatment schizophrenia ever, which is very important for the patient's convenience, the doctors, and the medical community, because there's no risk of relapse with hospitalization, increased mortality in the time that patients are switching their medication. We have those one-year results in phase II, highly statistically significant results in the phase III study. We are the first company ever to report 25% patients being in remission in treatment-resistant schizophrenia, remission being defined as no relevant symptoms over a period of six months of the one-year study. Drug has shown to be extremely safe in the phase III study that we have.
The most prevalent side effect was nasopharyngitis in a space where you have pound weight gain per week, sexual dysfunction, hormonal changes, Parkinson-like symptoms, 40% patients with nausea, vomiting, 3% patients with nasopharyngitis. No need to change the current medication. That's one of the major selling points for an add-on in a space where FDA has never approved an add-on because there's no good in adding one dopaminergic drug to another dopaminergic drug. It just makes side effects explode. That's what Bristol-Myers has shown very nicely in a phase III program when they wanted to take Karuna's drug as an add-on, and they failed. This drug will also work in bipolar depression and very importantly, in Alzheimer's with psychotic symptoms, and we intend to expand that space.
If you have something that you believe is special, first-in-class mechanism, first add-on, first drug in treatment-resistant schizophrenia since Lundbeck tried in 2018 and failed, you want to have long exclusivity. Right now, we have a composition of matter that's 2035, but we already have a new composition of matter submitted and granted in Europe to 2044, and soon you will see some additional territories added to that list. Hong Kong has been granted as well, and the process is ongoing in the U.S., China, and rest of world. So, we expect this new composition of matter patent to last until 2044. We have also submitted new formulation patents that would take us to 2045. Given that I'm presenting a lot of new to you want to see some validation. Yes, we didn't want to give up control of the compound.
We made that mistake with our Parkinson's drug, so we licensed just Japan and some parts of Asia to Eisai, a very experienced CNS innovator. They gave us a number of goodies. They gave us the validation of the mechanism, the positioning, and of the commercial potential. They gave us the money to run our phase III program, and they also gave us an indication of the fair value of the compound, because Jefferies, who helped us on the deal, did an rNPV calculation on all the payments in the future of that deal and arrived at no less than EUR 100 million rNPV for 7% of the global rights, which already in 2024 would have meant that the drug's global rights would have been EUR 1.5 billion. Total payments up to EUR 117 million down payment and milestones, and we already collected half of that by now.
There is additional milestones plus up to double-digit royalties. We also signed a deal with Myung In in South Korea. We are open to sign additional deals in Asia, means China, India, in Latin America, and potentially in Europe, but we will keep the U.S. rights because that is 50% of the world market. That allowed us, this deal and the money coming out from it, allowed us to start the pivotal program, ENIGMA-TRS 1. That study is going for more than 600 patients. In fact, we have completed enrollment in October. We have now 618 patients in that study. This is the first-ever one-year double-blind placebo-controlled study as an add-on in treatment-resistant schizophrenia with three readouts. After 12 weeks for the regulatory endpoints for FDA and EMA, after 26 weeks for the maintenance or long-term benefit, and then we go on to 52 weeks.
Given that we stay double-blind placebo-controlled, what you will get after 12 weeks is only a message saying the drug at 30 mg, the high dose, is statistically significant on the primary and secondary endpoint, and the drug is safe and well-tolerated. All the detailed results we will get after 26 weeks and after 52 weeks. As I said, study enrolling, results due in Q1 and Q2 of next year. ENIGMA-TRS 2, the second study, doesn't need a year to make it a pivotal study. It's just 12 weeks. It doesn't need three treatment arms, just two treatment arms, just placebo, which is standard of care, and placebo means standard of care plus low dose, and that is why it's only 400 patients. As you might know, from April 1, we are on hold on the four U.S. study centers. The study is enrolling ex-U.S. at full speed.
If we should not be able to strike an agreement with FDA in the next few weeks or a few months, I should say, then the study will complete enrollment and will deliver results from two pivotal studies in 1,000 patients ex-U.S. by Q3 of next year, and we will go into the NDA process, pre-NDA meeting, but possibly into advisory committee meeting, and we are very confident with the safety benefit ratio at that time. We will convince everybody that this, given the high unmet medical need in TRS, is the drug that should come to the patients' help. Why is this drug so different? We are not talking about dopamine. We are talking about a sodium channel blocker, a very special one. It comes without the usual seizures and arrhythmia topics. This drug is like a magic switch.
It turns on if there is need, which means if there's excessive firing neurons, and it will shut down if there's no excessively firing neurons. By that, it does modulate excessive release of glutamate, as you see in the right part of the chart, dose dependently, but it will not touch basal levels of glutamate. That's why we see the effects, but not the side effects. Now, we saw those phase II and phase III results, ever-increasing efficacy, almost straight line, 50% patients no longer treatment-resistant after one year, 25% in remission after one year. We couldn't explain how the drug does it. The University of Pittsburgh came to our help and said, "Look, if we look at schizophrenia, the way it develops, we believe it develops and starts at the hippocampus." But all today's drugs start working on the dopaminergic pathway, which is four levels down.
There's no way they can work back upwards to the origin. That's why they don't improve negative symptoms nor cognitive decline, and only part of the positive symptoms. The only drug that does repair the excessive firing of neurons at the hippocampus and the excessive release of glutamate at the hippocampus, which we see, is evenamide. And that's why in the model, our drug did improve all the subsections of what they found in that model. The most important finding that University of Pittsburgh had, though, was that this drug has a half-life of 20- 30 minutes. There's nothing left of this compound afterwards. But still, the improvements continued for hours after the drug was gone, which might be the explanation for our ever-increasing efficacy up to one year.
When the KOLs that we presented it to in three meetings, Canada, Europe, and United States, had to make their judgment on what it is, they came up with, "Well, it is obviously cleaning up the clogging in the system that we did have, possibly due to the dopaminergic treatment for many years." Wouldn't explain the 15% immediate treatment-resistant patients that we see and improve. Or it improves the neuronal interaction, and they call it neuronal plasticity, which would be a major promise for more than just schizophrenia. So what do we have to show to you? Let's start with the one-year phase II study add-on to antipsychotics in patients who are substantially severely ill, a PANSS total of 70- 90, PANSS positive more than 20, CGI-S 4- 6 on a seven scale. These patients are all on a stable dose of an antipsychotic.
I will say two grains of salt. Number one, it was open label. Number two, most patients came from India. Keep that in mind. The first surprise that we saw is in TRS, when you give a new drug, you expect 30%-35% patients to run away after four to six weeks, either because it doesn't work or the side effects are unbearable. After six weeks, we had 95% patients still in the study, and you see that even after one year, when patients were offered to stay for one year, 75% patients were still in the study after one year. Doctors said two reasons: must be safe and must work. No patients would tolerate a one-year study if it was not safe or did not work. Looking at the PANSS, which is the regulatory endpoint, you see we started at a PANSS baseline of 79.5.
You see that after six weeks, we improved by 12%, and people kept saying, "Well, that could be placebo." It looks good because it's TRS, and people shouldn't see any improvement, but we have seen 12%- 15% placebo improvement in the studies in the last 10 years. Could be that. But after six months, when the improvement increased to 16% and then to 19%, nobody could explain it any longer. It was not just reflected in the PANSS total, it was also CGI-C, CGI-S, and it was the level of functioning. Even more importantly, we looked at the responder analysis. How many of the patients did improve by minimally 20%? You see the rate doubles and triples up to one year, which is completely against all the teaching by FDA.
FDA says antipsychotics work quickly, they work to the plateau at four to six weeks, then they fade. You don't have to do studies beyond six weeks. We went for one year, we see ever-increasing efficacy. Then we looked at the inclusion criteria, which were the criteria by which we classified those patients to be treatment-resistant under the TRRIP criteria. You see, to cut it short, last bar right low, how many of the patients did fulfill any of the criteria by which they included? Half of the patients, treatment-resistant after one year, would no longer qualify as treatment-resistant. The icing on the cake was this one. There's no report ever of treatment-resistant schizophrenic patients being in remission, free from symptoms. One of the definitions is it should be for eight weeks, the other is 24 weeks.
We saw 25% of our patients being on the best medication the doctor could give them, still treatment-resistant after 12 months, 25% of our patients were free from relevant symptoms for at least six months. Everybody said, "Well, if that can be validated in a global, at least international, double-blind placebo-controlled study, that would be magic." We had that study, which was running overlapping, almost in parallel. It's a phase II/III study in 291 patients, double-blind placebo-controlled, run in 11 countries in the world. Again, those patients are on the best-selling antipsychotics, this time including clozapine, which is relevant because clozapine does not tolerate any other antipsychotic. Nobody has ever shown to improve clozapine. These patients were poor responders. Remember, poor responders to treatment-resistant is the vast majority of patients. Treatment-resistant is the final station. Poor responders is in between reasonably responding to dopaminergic, no longer responding.
This population was mixed, but 70% of them were qualifying as treatment-resistant. We did something nobody ever has done before. We didn't believe what the patient said, because the patient said, "I'm taking this drug." The doctor said, "Yes." The family said, "Yes." We took blood samples. Guess what? One-third of patients were non-compliant. They didn't make it into our study. That is one of the explanations, besides rigorous investigator training and investigator ranking. Investigators had to qualify. They had to take a test. If they didn't make it to the test, they had to re-qualify again, they might not have made it to the study. Everybody was randomized, 291 patients, you see the background medication. Our drug always came on top of the background medication and compared to the background medication alone, which is defined as placebo. The patients got 30 mg BID.
First, the safety profile. I mentioned it already. If you look at the first line of the second part, the worst we had was nasopharyngitis as a side effect in those patients on top of their medication. Compare that to the usual side effects. Then we got a highly statistically significant readout. Remember, I told you the efficacy of the drug goes up to one year, but already after four weeks, we have a P-value on the primary endpoint of 0.006. The treatment size, effect size is small, but we come to that. These are treatment-resistant patients. They should not benefit at all. They are on the best standard of care the doctor can give them. Also the secondary endpoint, CGI-S, was significant. This is the time curve, confirming again what I said. This is not a rapid onset.
This is a drug that takes its time to start working, but the farther you go, the more is the discrepancy to standard of care/placebo. On this study, this was the most remarkable slide, because this is the first drug to show that it improves clozapine patients. If you ever heard anybody saying that olanzapine was beaten in a head-to-head comparison, speak up, because our knowledge is olanzapine has never been beaten in a head-to-head comparison until this moment. This drug has beaten olanzapine into the ground, because olanzapine on its own improved patients by 7.9 points on the PANSS scale. We improved them, if we added to olanzapine, by 13.4 points. This was statistically significant in this super small subset of patients. If we look at the responder rates, again, it is very important I explain.
These patients are on the best medication the doctor can give them. If we compare only after four weeks, we add our drug to that, you see that we have twice the number of responders, meaning a 20% improvement on the PANSS total. The absolute same on CGI-C, and we are not looking at minimally improved. We are only looking at much or very much improved, practically twice the number of patients compared to standard of care, including clozapine, including olanzapine. That is what this drug has shown in that first phase III program. That led us, with the money and the reputation and the support by Eisai Group, to get into those two pivotal studies. ENIGMA-TRS 1, I mentioned it, the first-ever one-year double-blind placebo-controlled study with a compound, non-dopaminergic, non-cholinergic, add-on to standard of care in treatment-resistant patients.
What we do again, very importantly, the screening period is now doubled to 42 days. That is why it takes very long to enroll the patients. We take three times blood samples in those 42 days. In order to get to the 600 patients that we wanted to have, and we got 618 enrolled, so enrollment is completed, we had to screen 996 patients. Again, with everybody knowing this is coming, one-third of the candidates were non-compliant or didn't make it through the eligibility committee, because we have a global eligibility committee which is looking at every patient's dossier, headed by John Kane in New York, and they make absolutely sure that only those patients who are truly treatment-resistant by the same measures are getting into the study. We succeeded as per end of October.
Patients are all in, and that means 618 patients are now moving towards Q1 and the 12-week readout. Again, that will be staying double-blind placebo-controlled for the 26 weeks maintenance endpoint. Again, the PANSS total, and that 26 weeks endpoint, if positive, will make the European Medicines Agency to waive the request for a relapse prevention study. We will still go on for 52 weeks, mostly for pharmacoeconomic reasons. We want to confirm what we saw in the phase II study, the one and only drug that keeps improving patients, stabilizes them, no need to hospitalize, no relapses. We didn't have a single relapse in the one-year study in our phase II. No increased suicidality. That is the pharmacoeconomic promise, besides the fact that those patients have a promise that for the first time, there might be a treatment that changes the disease's trajectory to the better.
ENIGMA-TRS 2 is absolutely the same, with the only difference that it's cut short after 12 weeks, and it's only two treatment groups, which is standard of care plus placebo and standard of care plus low dose. That sums it all up. First-in-class glutamatergic modulator, first add-on, first treatment for ages since clozapine was approved in treatment-resistant schizophrenia. Large market opportunity. The study has shown to work in a tremendous, completely different way than you know everything or anything from schizophrenia treatments. Results coming in Q1, Q2, Q3 next year, and the team has done it before. Thank you. Happy to take any questions. Please.
Congratulations. Very, very impressive data. It's clear you know CNS. Now, with the mechanism that you explained and the clinical trial that you're doing, short-term, long-term, what is the label? What is the indication that you're going to seek? Did I understand correctly, it's an add-on? So it's an adjunctive therapy, or will you go to second, third lines and others?
This is an adjunctive treatment to patients who are treatment-resistant schizophrenic, and the additional labels would be either bipolar or depression. Our preferred label would be Alzheimer's with psychosis, because today's antipsychotics should not be used in that disease for increased mortality, and it is an indication where we might get approval with just one pivotal study.
[audio distortion]
It's tripling. If you take Intra-Cellular as an example, Intra-Cellular had a dopaminergic drug, which was, should I be allowed to say, me too? Intra-Cellular really took off when they got the bipolar label, and they made it a $680 million sales drug in the United States. The market cap was $9 billion, and they were acquired for $15 billion by J&J. I call that a deal. Sharon Mates, chapeau. This Alzheimer's psychosis has the same dimensions.
[audio distortion]
Please.
Do you have a depot in development?
No.
A depot in general.
No. The funny thing is, the difference of this drug compared to everything you have is, you don't need to cover a receptor for a certain period of time. It seems like this drug, excuse my wording, is a kick in the system. It is more important that you have one relevant kick in the system than to have a permanent coverage. That is the difference between this drug mechanism and what you have on the market today. Please.
How was the drug delivered
Yes. It is oral, it is twice a day, and in the phase III study in ENIGMA-TRS 1, it will be 15 or 30 mg BID, and in ENIGMA-TRS 2, it is 15 mg BID. Please.
In the data you showed us with olanzapine, are you seeing a difference between classes in terms of the nature [audio distortion] ?
I think my chief medical would say the numbers were not big enough to justify such a statement. It was especially impressive that given our different mechanism, we are the only ones who can help clozapine patients. Olanzapine, the second-best-selling antipsychotic of any times, is said to be the best efficacy-wise, and we have beaten them easily in patients who do no longer properly respond to olanzapine. No more questions? Here we go.
Why considering this mechanism of action, you are anyway treating with BID?
Yes. You could say, "Why don't you do once a day if it is just a kick in the system?" Because all our development from beginning to end has been done BID, so we would have to change it, redo, and we won't. Thank you. Have a good day.